Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Although TNF -α inhibitors and other RA biologics are generally considered efficacious and safe and adequately control disease in many conventional DMARD -refractory RA patients, therapies that are more effective in reducing the signs and symptoms of RA and that can sustain efficacy over time are needed. Novel agents able to demonstrate strong efficacy in these attributes will have substantial influence on physicians’ prescribing decisions for RA . We provide quantitative insight into and European rheumatologists’ perceptions of key treatment drivers and goals and the current level of unmet need in this indication. We analyze the commercial opportunities in the treatment of RA and discuss how emerging therapies can capitalize on these opportunities. Additionally, using an adaptive choice-based conjoint analysis, we offer an assessment of trade-offs, across clinical attributes and price, that can impact physicians’ prescribing likelihood and preference share of select target product profiles.
What are the treatment drivers and goals for RA ?
What attributes are key influences, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals for RA ?
What are the prevailing areas of unmet need and opportunity in RA ?
What trade-offs across different clinical attributes and price are acceptable to and European rheumatologists for a hypothetical new RA drug?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 and 31 European rheumatologists fielded in December 2016.
Key companies: AbbVie, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Incyte, Janssen, Pfizer, Roche
Key drugs: Humira, Remicade, Rituxan/MabThera, Orencia, Actemra/RoActemra, Xeljanz, baricitinib